XML 49 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Selected Quarterly Financial Data (Unaudited)
12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data (Unaudited)
The following are selected quarterly financial data for the years ended December 31, 2018 and 2017:
 
Quarter Ended
 
March 31,
2018
 
June 30,
2018
 
September 30,
2018
 
December 31, 2018
Revenues
$
2,468

 
$
2,358

 
$
2,847

 
$
2,755

Loss from operations
(9,908
)
 
(7,860
)
 
(6,417
)
 
(5,148
)
Net loss
(10,747
)
 
(8,664
)
 
(7,223
)
 
(5,941
)
Net loss per common share (basic and diluted)
$
(0.33
)
 
$
(0.26
)
 
$
(0.22
)
 
$
(0.18
)
Weighted average common shares (basic and diluted)
33,053,702

 
33,135,391

 
33,161,592

 
33,121,666

 
Quarter Ended
 
March 31,
2017
 
June 30,
2017
 
September 30,
2017
 
December 31, 2017
Revenues
$
2,131

 
$
2,061

 
$
2,444

 
$
3,262

Loss from operations
(15,053
)
 
(13,109
)
 
(14,471
)
 
(7,127
)
Net loss
(15,742
)
 
(14,090
)
 
(15,457
)
 
(8,028
)
Net loss per common share (basic and diluted)
$
(0.55
)
 
$
(0.49
)
 
$
(0.53
)
 
$
(0.24
)
Weighted average common shares (basic and diluted)
28,402,355

 
28,757,341

 
29,302,839

 
32,801,650


The net loss amounts presented for the quarters ended March 31, 2017 and September 30, 2017 include milestone payments of $3.8 million made under the Company’s collaboration with Aurigene, which were recognized as research and development expenses (see Note 4(b)).